Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.09) by 53.49 percent. This is a 84 percent increase over losses of $(0.25) per share from the same period last year.
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.09) by 53.49 percent. This is a 84 percent increase over losses of $(0.25) per share from the same period last year.
Comments